vTv Therapeutics Inc. ( VTVT ) is a late clinical-stage biopharmaceutical company that focuses on the development of therapies for Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and other chronic conditions. Its flagship candidate is Cadisegliatin (TTP399), an oral glucokinase activator beingMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, A ...

Company Overview - vTv Therapeutics Inc. is a late clinical-stage biopharmaceutical company focused on developing therapies for Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and other chronic conditions [1]. Key Product - The flagship candidate of the company is Cadisegliatin (TTP399), which is an oral glucokinase activator [1].

HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: Thursday, February 26, 2026Time: 11:20 AM ET ...